Viral Hepatitis at AASLD 2022: Newest Data
Newest Viral Hepatitis Data From AASLD 2022

Released: December 06, 2022

Stefan Zeuzem
Stefan Zeuzem, MD

Activity

Progress
1
Course Completed

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:

  • Hepatitis B
    • Prevention of HBV vertical transmission when HBIg is unavailable
    • Therapeutic vaccination for HBV cure
    • Antiviral therapy to prevent HCC in patients with CHB in the indeterminate phase
  • Hepatitis delta
    • HDV prevalence in ethnically diverse, urban, safety-net populations
    • Bulevirtide ± pegIFN-α2a for chronic HDV in the French cATU study
    • Bulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di study
    • HDV functional cure with lonafarnib-based therapy
  • Hepatitis C
    • Integrated community HCV service for PWUD: the ITTREAT study
    • Helios-3 study of treatment of people with HCV by specialists or nonspecialists
    • Risk of HCC after SVR in patients with HCV